O
Pioneering 3D bioprinting company developing functional human tissue models for drug discovery and regenerative medicine
About
Organovo Holdings is a pioneering 3D bioprinting company that designs and develops functional three-dimensional human tissue for medical research and therapeutic applications. Founded in 2007, Organovo uses its proprietary NovoGen MMX Bioprinter technology to create human tissue models used in pharmaceutical drug discovery, toxicology testing, and regenerative medicine research. The company's NAMKind™ Human-Based Toxicology Services platform has expanded internationally through distributor partnerships.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Organovo do?
Organovo Holdings is a pioneering 3D bioprinting company that designs and develops functional three-dimensional human tissue for medical research and therapeutic applications. Founded in 2007, Organovo uses its proprietary NovoGen MMX Bioprinter technology to create human tissue models used in pharmaceutical drug discovery, toxicology testing, and regenerative medicine research. The company's NAMKind™ Human-Based Toxicology Services platform has expanded internationally through distributor partn…
How much funding has Organovo raised?
Organovo has raised a total of $118M in funding.
Where is Organovo headquartered?
Organovo is headquartered in San Diego, United States.
When was Organovo founded?
Organovo was founded in 2007.
What industry does Organovo operate in?
Organovo operates in Biotech, Drug Discovery, Regenerative Medicine, Bioprinting, Life Sciences, Healthcare.